Shanghai, China, 19 August 2022 – MicroPort CardioFlow Medtech Corporation (“CardioFlow Medtech”) recently announced that its independently-developed transcatheter aortic valve implantation (TAVI) solution, the new-generation VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (“VitaFlow Liberty™”) has received marketing approval from the National Institute for Drug and Food Surveillance of Colombia.
VitaFlow Liberty™ inherits the unique design of the original VitaFlow® Transcatheter Aortic Valve and Delivery System (“VitaFlow®”), with an upgraded delivery system. Its unique double-reinforced spiral structure, not only provides for fast, stable and accurate release and retrieval, but also ensures superior flexibility and non-directionality, with a bendable distal end that can be bent 360 degrees.
In addition to VitaFlow Liberty™, CardioFlow Medtech's first-generation Angelguide™ preshaped super stiff guidewire (“Angelguide™”) was also approved for marketing in Colombia. The guidewire features high support and smooth transition for guidewire and guide trail, thus reducing blood vessel damage and improving release precision.
The successful launch of VitaFlow Liberty™ in Columbia represents yet another milestone in the internationalization of CardioFlow Medtech in Latin America after Argentina. The rapid growth of the VitaFlow® product line in Latin America in the field of valve intervention provides a boost for CardioFlow Medtech to enter more overseas markets with high potential.
In the future, CardioFlow Medtech will continue to accelerate the commercialization of innovative products with international competitiveness and introduce TAVI products to more countries and regions, bringing high-quality, universal total solutions for structural heart disease to more patients around the world.
About CardioFlow Medtech
Founded in Shanghai in 2015, MicroPort CardioFlow Medtech Corporation (“CardioFlow Medtech”, stock code: 02160.HK), a subsidiary of MicroPort Scientific Corporation ("MicroPort®", stock code: 00853.HK), is a leading medical device company in China focusing on research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart disease. The Company’s self-developed second-generation Transcatheter Aortic Valve Implantation (TAVI) product VitaFlow Liberty™ is the world’s only commercialized motorized retrievable system. In addition to the TAVI products, the Company has also established a strategic R&D pipeline covering Transcatheter Mitral Valve (TMV) therapies, Transcatheter Tricuspid Valve (TTV) therapies, surgical valve products and surgical accessories via independent development and collaboration with global partners. At CardioFlow Medtech, we strive to provide integrated therapeutic solutions for patients with heart valve disease, dedicated to providing high quality therapeutic solutions to patients and physicians across the globe.
More information is available at www.cardioflowmedtech.com.